Pharmacokinetics and Safety of Doripenem in hospitalized Pediatric Patients from 3 Months to 17 Years of Age

Registry ID

EUCTR2011-005159-15

Source registry

EUCTR

Phase

PHASE1

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Last update

2026-08-16

Conditions

• Bacterial infections

Summary

The primary objective of this study is to assess the pharmacokinetics of doripenem and its metabolite, doripenem-M-1, in pediatric subjects 3 months to 17 years of age, inclusive.

View on source registry